Bempegaldesleukin with nivolumab for untreated unresectable or metastatic melanoma
Discontinued [GID-TA10970]
Discontinued [GID-TA10970]
Discontinued [GID-TAG390]
Discontinued [GID-TAG402]
Discontinued [GID-TAG396]
Discontinued [GID-TAG372]
Discontinued [GID-MT544]
Discontinued [GID-TAG378]
Discontinued [GID-TA10236]
Discontinued [GID-TAG375]
Discontinued [GID-TAG398]
Discontinued [GID-TAG371]
Discontinued [GID-TAG370]
Discontinued [GID-TAG411]
Discontinued [GID-TA10462]
Discontinued [GID-MT81]
Discontinued [GID-TAG404]
Discontinued [GID-TAG368]
Discontinued [GID-MT516]
Discontinued [GID-TAG239]
Discontinued [GID-MT267]
Discontinued [GID-MT517]
Discontinued [GID-MT163]
Discontinued [GID-TAG385]
Discontinued [GID-TAG400]
Discontinued [GID-TAG416]
Discontinued [GID-TAG408]
Discontinued [GID-MT117]
Discontinued [GID-TA10087]
Discontinued [GID-TAG377]
Discontinued [GID-TAG241]
Discontinued [GID-MT130]
Discontinued [GID-TA10088]
Discontinued [GID-MT510]
Discontinued [GID-TA10502]
Discontinued [GID-TAG414]
Discontinued [GID-MT536]
Discontinued [GID-TAG399]
Discontinued [GID-TAG511]
Discontinued [GID-TAG382]
Discontinued [GID-TAG393]
Discontinued [GID-TAG397]
Discontinued [GID-TAG374]
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
Discontinued [GID-TA10081]
Discontinued [GID-TA10394]